FIH Study to Evaluate the Tolerability of PF-07832837
Phase 1
119
about 2.6 years
18–70
3 sites in CA, FL, PA
What this study is about
This trial is testing a treatment called PF-07832837 in healthy adults and people with atopic dermatitis. The goal is to see if this treatment is safe and how it works in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take PF-07832837
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs Following multiple ascending doses (MAD), Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs in participants with atopic dermatitis (AD), Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD), Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following MAD, Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SAD, Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SAD, Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SAD, Number of Participants with Clinically Significant Change from Baseline in Vital Signs in participants with AD
Secondary: Maximum Observed Serum Concentration (Cmax) of PF-07832837 following MAD, Maximum Observed Serum Concentration (Cmax) of PF-07832837 following SAD, Percent change from baseline in Eczema Area and Severity Index (EASI) total score at Week 8, Terminal serum elimination half life (t1/2) of PF-07832837 following SAD, Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-07832837 following MAD, Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-07832837 following SAD
Dermatology